BACKGROUND/AIMS: There are racial and geographic disparities in stroke mortality, with higher rates among African Americans (AAs) and those living in the southeastern US ('stroke belt'). Racial and geographic differences in dyslipidemia prevalence, awareness, treatment and control may, in part, account for the observed disparities in stroke mortality. METHODS: Reasons for Geographic and Racial Differences in Stroke (REGARDS) is a national observational study of community-dwelling black and white participants aged 45 and older, with oversampling from the stroke belt. As of January 15, 2007, 26,122 participants were enrolled and a fasting lipid panel was available of 21,068. Awareness, treatment and control of dyslipidemia were estimated overall and compared across race-sex-region strata. RESULTS: There were 55% of the participants with dyslipidemia and no racial differences in prevalence. Adjusting for demographic and established stroke risk factors, AAs had a lower prevalence (OR 0.74; 95% CI: 0.66, 0.77) and were less likely to be aware (0.69; 0.61, 0.78), treated (0.77; 0.67, 0.89) and controlled (0.67; 0.58, 0.77) than whites. There was lower control outside of the stroke belt (0.87; 0.76, 0.99). CONCLUSION: Racial, but not geographic, differences in dyslipidemia management may play a role in the excess stroke burden in the Southeast.
BACKGROUND/AIMS: There are racial and geographic disparities in stroke mortality, with higher rates among African Americans (AAs) and those living in the southeastern US ('stroke belt'). Racial and geographic differences in dyslipidemia prevalence, awareness, treatment and control may, in part, account for the observed disparities in stroke mortality. METHODS: Reasons for Geographic and Racial Differences in Stroke (REGARDS) is a national observational study of community-dwelling black and white participants aged 45 and older, with oversampling from the stroke belt. As of January 15, 2007, 26,122 participants were enrolled and a fasting lipid panel was available of 21,068. Awareness, treatment and control of dyslipidemia were estimated overall and compared across race-sex-region strata. RESULTS: There were 55% of the participants with dyslipidemia and no racial differences in prevalence. Adjusting for demographic and established stroke risk factors, AAs had a lower prevalence (OR 0.74; 95% CI: 0.66, 0.77) and were less likely to be aware (0.69; 0.61, 0.78), treated (0.77; 0.67, 0.89) and controlled (0.67; 0.58, 0.77) than whites. There was lower control outside of the stroke belt (0.87; 0.76, 0.99). CONCLUSION: Racial, but not geographic, differences in dyslipidemia management may play a role in the excess stroke burden in the Southeast.
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: Arterioscler Thromb Vasc Biol Date: 2004-08 Impact factor: 8.311
Authors: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren Journal: Lancet Date: 2003-04-05 Impact factor: 79.321
Authors: R L Sacco; R T Benson; D E Kargman; B Boden-Albala; C Tuck; I F Lin; J F Cheng; M C Paik; S Shea; L Berglund Journal: JAMA Date: 2001-06-06 Impact factor: 56.272
Authors: Brett Kissela; Alexander Schneider; Dawn Kleindorfer; Jane Khoury; Rosemary Miller; Kathleen Alwell; Daniel Woo; Jerzy Szaflarski; James Gebel; Charles Moomaw; Arthur Pancioli; Edward Jauch; Rakesh Shukla; Joseph Broderick Journal: Stroke Date: 2004-02 Impact factor: 7.914
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321
Authors: Mark W Massing; Kathleen A Foley; Lori Carter-Edwards; Carla A Sueta; Charles M Alexander; Ross J Simpson Journal: BMC Cardiovasc Disord Date: 2004-08-18 Impact factor: 2.298
Authors: Monika M Safford; Christopher M Gamboa; Raegan W Durant; Todd M Brown; Stephen P Glasser; James M Shikany; Richard M Zweifler; George Howard; Paul Muntner Journal: Am J Prev Med Date: 2015-05 Impact factor: 5.043
Authors: Mukaila A Raji; Matthew Lowery; Yu-Li Lin; Yong-Fang Kuo; Jacques Baillargeon; James S Goodwin Journal: Ann Pharmacother Date: 2013-01-16 Impact factor: 3.154
Authors: George Howard; Claudia S Moy; Virginia J Howard; Leslie A McClure; Dawn O Kleindorfer; Brett M Kissela; Suzanne E Judd; Fredrick W Unverzagt; Elsayed Z Soliman; Monika M Safford; Mary Cushman; Matthew L Flaherty; Virginia G Wadley Journal: Stroke Date: 2016-06-02 Impact factor: 7.914
Authors: Kosmas I Paraskevas; Dimitri P Mikhailidis; Hediyeh Baradaran; Alun H Davies; Hans-Henning Eckstein; Gianluca Faggioli; Jose Fernandes E Fernandes; Ajay Gupta; Mateja K Jezovnik; Stavros K Kakkos; Niki Katsiki; M Eline Kooi; Gaetano Lanza; Christos D Liapis; Ian M Loftus; Antoine Millon; Andrew N Nicolaides; Pavel Poredos; Rodolfo Pini; Jean-Baptiste Ricco; Tatjana Rundek; Luca Saba; Francesco Spinelli; Francesco Stilo; Sherif Sultan; Clark J Zeebregts; Seemant Chaturvedi Journal: J Stroke Date: 2021-05-31 Impact factor: 6.967
Authors: Gabriel S Tajeu; Monika M Safford; George Howard; Virginia J Howard; Ligong Chen; D Leann Long; Rikki M Tanner; Paul Muntner Journal: Am J Public Health Date: 2020-03-19 Impact factor: 9.308